Infrared microspectroscopy and imaging analysis of inflammatory and non-inflammatory breast cancer cells and their GAG secretome

dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorMohamed, Hossam Taha
dc.contributor.authorUntereiner, Valérie
dc.contributor.authorCinque, Gianfelice
dc.contributor.authorIbrahim, Sherif Abdelaziz
dc.contributor.authorGötte, Martin
dc.contributor.authorNguyen, Nguyet Que
dc.contributor.authorRivet, Romain
dc.contributor.authorSockalingum, Ganesh D.
dc.contributor.authorBrézillon, Stéphane
dc.date.accessioned2020-10-03T09:49:32Z
dc.date.available2020-10-03T09:49:32Z
dc.date.issued9/19/2020
dc.descriptionScopusen_US
dc.description.abstractGlycosaminoglycans (GAGs)/proteoglycans (PGs) play a pivotal role in the metastasis of inflammatory breast cancer (IBC). They represent biomarkers and targets in diagnosis and treatment of different cancers including breast cancer. Thus, GAGs/PGs could represent potential prognostic/diagnostic biomarkers for IBC. In the present study, non-IBC MDA-MB-231, MCF7, SKBR3 cells and IBC SUM149 cells, as well as their GAG secretome were analyzed. The latter was measured in toto as dried drops with high-throughput (HT) Fourier Transform InfraRed (FTIR) spectroscopy and imaging. FTIR imaging was also employed to investigate single whole breast cancer cells while synchrotron-FTIR microspectroscopy was used to specifically target their cytoplasms. Data were analyzed by hierarchical cluster analysis and principal components analysis. Results obtained from HT-FTIR analysis of GAG drops showed that the inter-group variability enabled us to delineate between cell types in the GAG absorption range 1350–800 cm−1. Similar results were obtained for FTIR imaging of GAG extracts and fixed single whole cells. Synchrotron-FTIR data from cytoplasms allowed discrimination between non-IBC and IBC. Thus, by using GAG specific region, not only different breast cancer cell lines could be differentiated, but also non-IBC from IBC cells. This could be a potential diagnostic spectral marker for IBC detection useful for patient management. © 2020 by the authors. Licensee MDPI, Basel, Switzerlanden_US
dc.description.sponsorshipEuropean Commission 645756,H2020-MSCA-RISE-2014en_US
dc.identifier.doihttps://doi.org/10.3390/molecules25184300
dc.identifier.issn14203049
dc.identifier.otherhttps://doi.org/10.3390/molecules25184300
dc.identifier.urihttp://repository.msa.edu.eg/xmlui/handle/123456789/3806
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofseriesMolecules;Volume 25, Issue 18, September 2020, Article number 4300
dc.subjectinflammatory breast canceren_US
dc.subjectglycosaminoglycansen_US
dc.subjectproteoglycansen_US
dc.subjectsecretomeen_US
dc.subjectinfrared (micro)spectroscopyen_US
dc.subjectimagingen_US
dc.subjectsynchrotron-FTIRen_US
dc.titleInfrared microspectroscopy and imaging analysis of inflammatory and non-inflammatory breast cancer cells and their GAG secretomeen_US
dc.typeArticleen_US

Files